Literature DB >> 25793426

IL-17, IL-23, and p73 expression in cutaneous melanoma: a pilot study.

Giulia Ganzetti1, Corrado Rubini, Anna Campanati, Antonio Zizzi, Elisa Molinelli, Laura Rosa, Francesco Simonacci, Annamaria Offidani.   

Abstract

The incidence of cutaneous malignant melanoma is increasing worldwide, resulting in the demand for clinically useful prognostic biomarkers, especially for invasive and metastatic disease. We studied the immunohistochemical expression of interleukin-17 (IL-17), IL-23, and p73 in 35 malignant melanomas and compared them with benign melanocytic nevi and Spitz nevi, correlating them with clinical-pathological variables. A higher and statistically significant difference (P<0.05) in the intensity and percentage of stained cells of IL-17 and IL-23 was found in the melanoma group than in ordinary benign nevi that did not correlate with Breslow thickness nor Clark level. Moreover, p73 staining and percentage of stained cells was significantly higher (P<0.05) in all the melanomas studied, with a peculiar cytoplasmatic distribution. Our findings could suggest a possible IL-17, IL-23, and p73 involvement in cutaneous melanomas with a hypothetical impact on melanoma invasiveness.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25793426     DOI: 10.1097/CMR.0000000000000151

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  12 in total

Review 1.  Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer.

Authors:  Juming Yan; Mark J Smyth; Michele W L Teng
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

2.  Cancer Immune Equilibrium and Schizophrenia Have Similar Interferon-γ, Tumor Necrosis Factor-α, and Interleukin Expression: A Tumor Model of Schizophrenia.

Authors:  James S Brown
Journal:  Schizophr Bull       Date:  2016-05-11       Impact factor: 9.306

Review 3.  Clinical implications of the deregulated TP73 isoforms expression in cancer.

Authors:  N Rodríguez; A Peláez; R Barderas; G Domínguez
Journal:  Clin Transl Oncol       Date:  2017-12-11       Impact factor: 3.405

4.  Skin Inflammation Modulation via TNF-α, IL-17, and IL-12 Family Inhibitors Therapy and Cancer Control in Patients with Psoriasis.

Authors:  Daniel Octavian Costache; Oana Feroiu; Adelina Ghilencea; Mihaela Georgescu; Ana Căruntu; Constantin Căruntu; Sorin George Țiplica; Mariana Jinga; Raluca Simona Costache
Journal:  Int J Mol Sci       Date:  2022-05-06       Impact factor: 6.208

5.  Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy.

Authors:  Vincent T Ma; Christopher D Lao; Leslie A Fecher; Elena Schiopu
Journal:  Immunotherapy       Date:  2022-04-13       Impact factor: 4.040

6.  PLK2 phosphorylates and inhibits enriched TAp73 in human osteosarcoma cells.

Authors:  Zheng Bo Hu; Xiao Hong Liao; Zun Ying Xu; Xiao Yang; Chao Dong; An Min Jin; Hai Lu
Journal:  Cancer Med       Date:  2015-12-02       Impact factor: 4.452

7.  Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments.

Authors:  Cristina Pellegrini; Augusto Orlandi; Gaetana Costanza; Alessandro Di Stefani; Antonella Piccioni; Antonella Di Cesare; Andrea Chiricozzi; Amedeo Ferlosio; Ketty Peris; Maria Concetta Fargnoli
Journal:  PLoS One       Date:  2017-08-22       Impact factor: 3.240

8.  Expression profiles of p53/p73, NME and GLI families in metastatic melanoma tissue and cell lines.

Authors:  Petar Ozretić; Nikolina Hanžić; Bastien Proust; Maja Sabol; Diana Trnski; Martina Radić; Vesna Musani; Yari Ciribilli; Ivan Milas; Zvonimir Puljiz; Maja Herak Bosnar; Sonja Levanat; Neda Slade
Journal:  Sci Rep       Date:  2019-08-28       Impact factor: 4.379

9.  TP73 is a credible biomarker for predicting clinical progression and prognosis in cervical cancer patients.

Authors:  Hui Ye; Xia Guo
Journal:  Biosci Rep       Date:  2019-08-05       Impact factor: 3.840

Review 10.  IL-17 and its role in inflammatory, autoimmune, and oncological skin diseases: state of art.

Authors:  Nicoletta Bernardini; Nevena Skroza; Ersilia Tolino; Alessandra Mambrin; Alessia Anzalone; Veronica Balduzzi; Daniela Colapietra; Anna Marchesiello; Simone Michelini; Ilaria Proietti; Concetta Potenza
Journal:  Int J Dermatol       Date:  2019-10-30       Impact factor: 2.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.